In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023, Cipla has informed that it enclosed a disclosure in Annexure-1 and a press release dated 22nd May 2024 titled ‘Cipla receives final approval for the generic version of Somatuline® Depot (lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL’.
The above information is a part of company’s filings submitted to BSE.
